InsidersTradesSigma
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
Discover the complete record of transactions filed by Countouriotis Athena, 首席执行官. Director active across 3 companies, notably Turning Point Therapeutics, Inc.. Aggregated, 10 disclosures have been published. Split: 0 buy · 1 sell. Total volume traded: €94k. History available since 9 February 2022. The latest transaction was filed on 2 June 2026 (Attribution). Regulator: SEC (Form 4). The full history is free.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
10 条申报中的 10 条
Countouriotis Athena is President and Chief Executive Officer. She has 10 filings in total. In the sampled recent filings, they span from 2016-01-04 to 2026-06-04 and show EUR 8,378,049 of sales and EUR 0 of purchases. The main recent filings concern Turning Point Therapeutics, Inc., with sales published on 2022-08-17 and 2022-02-11, as well as several Attribution transactions at Biomarin Pharmaceutical INC.